Background
==========

Transdifferentiation of the liver epithelial cells (hepatocytes and biliary cells) into each other provides a rescue mechanism in liver disease under the situations where either cell compartment fails to regenerate by itself. We have previously reported transdifferentiation of hepatocytes into biliary epithelial cells (BEC) both in *in vivo*rat model using biliary toxicant 4,4\'-methylenedianiline \[diaminodiphenyl methane, (DAPM)\] followed by biliary obstruction induced by bile duct ligation (BDL) \[[@B1]\] and *in vitro*using hepatocyte organoid cultures treated with hepatocyte growth factor (HGF) and epidermal growth factor (EGF) \[[@B2]-[@B4]\]. Other investigators have also demonstrated hepatocyte-to-BEC transdifferentiation in hepatocyte cultures \[[@B5]\] and following hepatocyte transplantation in spleen \[[@B6]\]. In humans, chronic biliary liver diseases (CBLD) characterized by progressive biliary epithelial degeneration are also known to be associated with formation of intermediate hepatobiliary cells expressing both hepatocytic and biliary specific markers \[[@B7]-[@B9]\]. However, the mechanisms promoting such hepatocyte to BEC transdifferentiation (or vice versa) are not completely understood. In the current study, by repeatedly injuring biliary cells by minimally toxic dose of DAPM administered to rats we established a novel rodent model resembling CBLD \[[@B10]\]. DAPM selectively injures biliary cells because toxic metabolites of DAPM are excreted in bile \[[@B10],[@B11]\].

Orchestrated network of liver-enriched transcription factors is known to play an important role in pre- and postnatal liver development as well as in lineage specification of hepatoblasts into hepatocytes and BECs \[[@B12],[@B13]\]. Studies with knockout mice have shown that hepatocyte nuclear factor (HNF) 1α and HNF4α regulate transcription of genes essential for the hepatocytic lineage \[[@B14]-[@B16]\] whereas HNF1β and HNF6 are involved in development of the gallbladder and bile ducts \[[@B17]-[@B19]\]. In the present study, the expression of hepatocyte- and biliary-specific HNFs is examined during reprogramming of cell lineage during transdifferentiation using DAPM + BDL and repeated DAPM treatment models.

Gradient of TGFβ expression regulated by Onecut transcription factor HNF6 in ductal plate hepatoblasts during embryonic liver development is crucial for biliary differentiation \[[@B20]\]. In the present study, TGFβ1 and HNF6 expression pattern was studied in order to determine if similar mechanism is recapitulated during hepatocyte to BEC transdifferentiation in the adult liver. The likely source of hepatocytes capable of functioning as progenitor cells in the event of compromised biliary regeneration is investigated by assessing expression of biliary specific keratin CK19.

To examine if hepatocytes transdifferentiate into biliary epithelium after repeated administration of DAPM, dipeptidyl peptidase IV (DPPIV) chimeric rats were utilized that normally carry DPPIV-positive population of only hepatocytes derived from donor DPPIVpositive rats \[[@B21],[@B1]-[@B3]\]. Neither the hepatocytes nor the BECs express DPPIV in the recipient DPPIV negative rats. Thus, appearance of biliary epithelial cell clusters positive for the hepatocyte marker DPPIV provides strong evidence that BEC are derived from hepatocytes.

Results
=======

Histological and functional bile duct damage after DAPM administration
----------------------------------------------------------------------

Biliary toxicity induced by single administration of DAPM (50 mg/kg, ip) was monitored by elevations of serum bilirubin and histopathological observations over a time course. Maximum biliary injury in terms of serum bilirubin was apparent by 24 h and consistently stayed high till 48 h after DAPM (Figure [1A](#F1){ref-type="fig"}). By day 7, rats appeared to recover from toxicity as indicated by regressing serum bilirubin levels (Figure [1A](#F1){ref-type="fig"}). Histopathological observations revealed biliary cell necrosis as early as 12 h after DAPM. Necrosis was accompanied by ductular swelling and inflammation. Some damage to the hepatocytes was also observed in the form of bile infarcts. However, the serum ALT elevations were minimal suggesting hepatocyte injury by DAPM was secondary (Additional File [1](#S1){ref-type="supplementary-material"}, Figure S1). Based on the quantitative analysis, 70% bile ducts were injured by DAPM at 24 h after DAPM. At 48 h, the bile ducts appeared to be repairing from injury (Figure [1B](#F1){ref-type="fig"}). The PCNA analysis indicated that the biliary cells begin cell division at 48 h and continue till day 7 (Figure [1C](#F1){ref-type="fig"}). Based on these findings, we chose to administer DAPM (50mg/kg, ip) every 2 days for total 3 times in order to inflict repeated biliary injury and simultaneously impairing their ability to regenerate themselves. It should be noted that it is the same dose of DAPM that was used in our previous study using DAMP + BDL injury model \[[@B1]\].

![**Biliary injury and regeneration following DAPM toxicity**. **(A)** Serum bilirubin levels indicative of biliary injury after DAPM (50 mg/kg) administration in F344 rats over a time course. \* indicates statistical difference from the 0h control (P ≤ 0.05). **(B)**Histopathology of the liver following DAPM toxicity (50 mg/kg) depicted by H&E staining. Arrow points to the biliary injury. **(C)**Biliary regeneration after DAPM (50 mg/kg) toxicity depicted by PCNA immunohistochemistry. Brown staining indicates PCNA positive cells. Thin arrow indicates regenerating biliary ductules. Arrowhead points to the hepatocyte proliferation. Scale bar = 100 μm.](1476-5926-9-9-1){#F1}

Appearance of DPPIV-positive bile ducts after repeated administration of DAPM
-----------------------------------------------------------------------------

The DPPIV chimeric rats were injected with DAPM at day 0, day 2, and day 4 (Figure [2A](#F2){ref-type="fig"}). On day 30 after the last injection of DAPM the rats were sacrificed and the liver sections from various lobes were examined for DPPIV positivity. Before DAPM administration, there was 40%-50% engraftment of the DPPIV-positive hepatocytes as reported before and none of the biliary cells were DPPIV-positive (Figure [2B](#F2){ref-type="fig"}). After DAPM repeated administration \~20% of the bile ducts turned DPPIV-positive indicating that they are derived from DPPIV positive hepatocytes (Figure [2C](#F2){ref-type="fig"}).

![**Appearance of DPPIV in bile ducts cells after repeated DAPM administration (DAPM × 3)**.**(A)** Schematic representation of repeated DAPM administration protocol. DAPM (50 mg/kg) administered at day 0, 2, and 4 to the DPPIV chimeric rats. Rats sacrificed at day 30 after the last DAPM injection. DPPIV staining before **(B)** and after **(C)** repeated DAPM administration to the DPPIV chimeric rats. Arrowheads point to the DPPIV positive bile ducts. Arrows indicate DPPIV negative bile ducts. The number of DPPIV positive bile ducts was determined after counting DPPIV positive bile ductules in liver sections obtained from different lobes of liver from 3 individual rats separately. None of the bile duct cells of the DPPIV chimeric rats were positive before DAPM treatment. \~20% bile ducts were noted to be DPPIV positive after DAPM × 3 protocol. Scale bar = 100 μm.](1476-5926-9-9-2){#F2}

Periportal hepatocyte expression of CK19
----------------------------------------

CK19 was expressed only in BEC in the normal liver (Figure [3A](#F3){ref-type="fig"}). However, after DAPM treatment protocol, selective periportal hepatocytes were also strongly positive for CK19 in addition to the BEC (Figure [3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}). Periportal hepatocytic CK19 staining was not uniform across the liver lobule. These findings indicate that the periportal hepatocytes only in the proximity of the affected biliary cells offer a pool of facultative stem cells capable of transdifferentiation to biliary cells.

![**Localization of CK19 following DAPM + BDL or repeated DAPM treatment (DAPM × 3)**. **(A)**Normal rat liver (NRL), (**B**) liver from DAPM + BDL treated rat, **(C)**liver from repeated DAPM treatment (DAPM x3). Brown color indicates CK19 positive staining. **Arrows**indicate bile duct staining. Arrowheads indicate hepatocytic staining. PV, portal vein; BD, bile duct. Scale bar = 100 μm.](1476-5926-9-9-3){#F3}

Hepatocyte-associated transcription factor HNF4 α expression in newly formed biliary ductules
---------------------------------------------------------------------------------------------

Figure [4](#F4){ref-type="fig"} depicts the HNF4α (Figure [4A, B](#F4){ref-type="fig"}, and [4C](#F4){ref-type="fig"}) and CK19 (Figure [4D, E](#F4){ref-type="fig"}, and [4F](#F4){ref-type="fig"}) stainings on the serial liver sections. In the normal rat liver, nuclear HNF4α expression is observed only in the hepatocytes (Figure [4A](#F4){ref-type="fig"}). However, the biliary ductules undergoing repair after repeated DAPM administration or DAPM + BDL show incorporation of cells resembling hepatocyte morphology that also had HNF4α positive staining (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}, respectively). In Figure [4C](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"} there is a panel of ductules in which only some of the cells in a duct are HNF4α positive and only some of the cells are CK19 positive (with overlap between some of the cells).

![**HNF4α and CK19 immunohistochemistry**. Liver sections obtained from normal control rats (NRL, normal rat liver) **(A and D)**, rats that underwent DAPM + BDL treatment **(B and E)**, or repeated DAPM treatment (DAPM × 3) **(C and F)**. **B**, **E** and **C**, **F** are serial sections. Brown nuclear staining indicated HNF4α positive cells in the left panel. Brown cytoplasmic staining in the right panel indicates CK19 positive cells. NRL bile ducts are HNF4α- negative and CK19 positive. However, after DAPM + BDL and DAPM × 3 treatment bile ducts turn HNF4α positive along with CK19. In addition, periportal hepatocytes also turn positive for CK19 after BDL + DAPM and DAPM × 3 treatment. PV, portal vein; BD, bile duct. Scale bar = 100 μm.](1476-5926-9-9-4){#F4}

Appearance of biliary-specific transcription factor HNF1β in hepatocytes intercalated within biliary ductules
-------------------------------------------------------------------------------------------------------------

HNF1β staining is observed only in the biliary nuclei of the normal rat liver (Figure [5A](#F5){ref-type="fig"}) but not in the hepatocytes. After DAPM + BDL injury (Figure [5B](#F5){ref-type="fig"}) and repeated DAPM toxicity (Figure [5C](#F5){ref-type="fig"}), many cells which morphologically appear as hepatocytes are seen intercalated within biliary ductules that coexpress HNF4α, indicating their hepatocytic origin. Many (but not all) of these cells stain positive for HNF1β (Figure [5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}). Notice the ductules marked with a thin arrow shown as an example have HNF1β stain, but are HNF4α- negative (Figure [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). The cells coexpressing HNF1β and HNF4α appear bigger compared to the normal liver biliary cells, a characteristic of ductular reaction.

![**HNF1β and HNF4α immunohistochemistry on serial liver sections**. **(A)**normal control rats (NRL, normal rat liver), **(B)**rats that underwent DAPM + BDL treatment, or **(C)**repeated DAPM treatment (DAPM × 3). HNF1β and HNF4α coexpressing cells are pointed by an arrow. HNF1β positive but HNF4α negative bile ducts pointed by circles. PV, portal vein; BD, bile duct. Scale bar = 100 μm.](1476-5926-9-9-5){#F5}

Transforming growth factor beta 1 (TGFβ1) induction in the periductular region with no change in HNF6 staining
--------------------------------------------------------------------------------------------------------------

Compared to controls (Figure [6A](#F6){ref-type="fig"}), TGFβ1 induction was observed in the region surrounding the biliary ductules after DAPM treatment in both the models under study (Figure [6B](#F6){ref-type="fig"} and [6C](#F6){ref-type="fig"}). TGFβ1 Western blot data indicated increasing trend in both the treatment protocols compared to the controls (Figure [6D](#F6){ref-type="fig"}), although DAPM + BDL treatment did not show statistical significance from the normal rat liver (NRL) by densitometry. In the control liver (NRL), nuclear HNF6 staining was noticed in hepatocytes and biliary cells (Additional File [2](#S2){ref-type="supplementary-material"}, Figure S2, A). However, after DAPM toxicity, no significant change in HNF6expression was observed (Additional File [2](#S2){ref-type="supplementary-material"}, Figure S2, B and C).

![**TGFβ1 immunohistochemistry**. Induction of TGFβ1 in the periportal region after DAPM + BDL **(B)**and DAPM × 3 treatment **(C)**was observed compared to NRL **(A)**. Western blot analysis of TGFβ1 after DAPM + BDL and DAPM × 3 treatment using liver whole cell lysates. \*P ≤ 0.05. Scale bar = 100 μm.](1476-5926-9-9-6){#F6}

Discussion
==========

Mature hepatocytes and BECs contribute to the normal cell turnover and respond to various types of liver injuries towards self renewal \[[@B22],[@B23]\]. However, when their own capacity to proliferate is compromised, both hepatocytes and BECs can act as facultative stem cells for each other and compensate for the lost liver tissue mass \[[@B1],[@B23],[@B24]\]. Presence of the full time uncommitted stem cells in the liver has been argued historically. Studies have shown that under compromised hepatocyte proliferation, biliary cells transdifferentiate into mature hepatocytes via the \"oval cell\" (also known as the progenitor cell) pathway \[[@B25],[@B26]\]. When biliary cells are destroyed by DAPM under compromised hepatocyte proliferation, the oval cells do not emerge indicating that biliary cells are the primary source of oval cells \[[@B27],[@B28]\]. Supporting this notion, hepatocyte-associated transcription factor expression by bile duct epithelium and emerging oval cells is observed in the experimental oval cell activation induced by using 2 acetyl aminofluorene (2AAF) + partial hepatectomy (PHx) model \[[@B29]\] and also in cirrhotic human liver \[[@B9],[@B26]\].

Previously, we demonstrated that hepatocytes can also transdifferentiate into biliary cells under compromised biliary proliferation \[[@B1]-[@B4],[@B9]\]. Periportal hepatocytes can transform into BEC when the latter are destroyed by DAPM and proliferation of biliary epithelium is triggered by bile duct ligation. Under this compromised biliary proliferation, biliary ducts still appeared and newly emerging ductules carried hepatocyte marker DPPIV in the chimeric liver \[[@B1]\]. These findings demonstrate that hepatocytes serve as facultative stem cells for the biliary epithelium upon need. In the present study, a novel rodent model of repeated biliary injury was established by repeated low dose of DAPM given to rats. Using this novel model of repeated DAPM treatment regimen, we demonstrate that hepatocytes undergo transdifferentiation into biliary epithelium also during progressive biliary damage. DAPM produces specific injury to the biliary cells because its toxic metabolites are excreted in bile \[[@B10],[@B11]\]. In the DPPIV chimeric rats, bile ducts do not express DPPIV before DAPM administration; however, after repeated DAPM treatment \~20% of the biliary ductules express DPPIV, indicating that they are derived from hepatocytes. In the chimeric liver, 50% of the hepatocytes are derived from DPPIV + donor liver.

Therefore, it is possible that DPPIV negative hepatocytes also transform into BEC, however cannot be captured due to lack of DPPIV tag. As per the assumption \~40-50% ducts are derived by transdifferentiation (\~20 + % by DPPIV-positive hepatocytes + \~20 + % by DPPIV-negative hepatocytes). The rest of the ducts did not require repair because of lack of injury while part of the restoration can be due to some biliary regeneration itself that escaped repeated DAPM injury. After single DAPM injection, \~70% of the ducts were injured.

DPPIV is expressed only in the hepatocytes in the chimeric rats before DAPM treatment and therefore provides strong evidence that DPPIV-positive biliary cells are originated from hepatocytes after DAPM treatment. The longest time point studied in the present study is 30 days after the DAPM treatment when biliary restoration is still underway. It is possible that the biliary cells derived from hepatocytes will suspend the expression of DPPIV as the restoration process come to an end.

It can be argued that the biliary cells from the donor liver are the source of new biliary cells observed in the chimeric liver. However, after collagenase perfusion of the donor liver only \<5% contamination of small admixture of nonparenchymal cells including biliary, stellate, endothelial, and other cell types was noticed as in routine hepatocyte preparations. In addition, the chimeric rats are treated with DAPM that targets biliary cells specifically. Therefore it is unlikely that newly appearing biliary cells originate from the very small if any biliary contamination engrafted in the chimeric liver. In the chimeric rats, after a thorough examination, not a single DPPIV-positive bile duct epithelial cell was observed in total 45 portal triads examined in the sections taken randomly. DPPIV positive biliary cells are observed in the chimeric liver only after the DAPM treatment regimen.

During liver development both hepatocytes and BECs differentiate from hepatoblasts. The lineage-specific differentiation is regulated by cell-specific gene expression in turn controlled primarily by distinct sets of transcription factors \[[@B30],[@B31]\]. Altered patterns of cell specificity in the expression of the transcription factors between hepatocytes and BECs has been observed under severe hepatic necrosis and chronic biliary disease in human patients \[[@B9],[@B26]\] as well as in experimental conditions of 2AAF + PHx treatment \[[@B29]\]. In the present study, expression of the hepatocyte-specific transcription factor HNF4α was observed in the newly repairing ductules after DAPM + BDL and repeated DAPM injury. The newly repaired biliary ductules showed appearance of hepatocyte-like cells carrying HNF4α expression. It is interesting to note that the level of the HNF4α expression in repairing ductular cells was lower compared to normal hepatocytes suggesting its gradual loss during reprogramming towards biliary phenotype.

Consistent with that notion, HNF4α expressing ductular cells also expressed HNF1β, a BEC-specific transcription factor. Specific inactivation of Hnf1β gene in hepatocytes and bile duct cells using the Cre/loxP system results in abnormalities of the gallbladder and intrahepatic bile ducts, suggesting an essential function of Hnf1β in bile duct morphogenesis \[[@B17]\]. Gain of expression of HNF1β by the hepatocytes normally expressing HNF4α indicates switch to the biliary specification of these cells.

In order to examine if the mechanisms that govern the differentiation of hepatoblasts into BECs are recapitulated during transdifferentiation of mature hepatocytes into BECs, expression of TGFβ1 and Onecut factor HNF6 were assessed. During liver embryogenesis, a gradient of TGFβ signaling has been shown to control ductal plate hepatoblasts differentiation \[[@B20]\]. High TGFβ1 signaling is observed near the portal vein and is considered responsible for differentiation of hepatoblasts into biliary cells. The Onecut transcription factor HNF6, not expressed in the immediate periportal hepatoblasts inhibits TGFβ signaling in the parenchyma, and this allows normal hepatocyte differentiation. In the present study, an induction of TGFβ1 was observed in the hepatocytes the area surrounding the repairing biliary ductules, reminiscent of the changes seen in embryonic development. However, HNF6 immunohistochemistry did not reveal significant changes after DAPM treatment in both the models under study. TGFβ1 induction was also observed in the *in vitro*hepatocyte organoid cultures undergoing biliary transdifferentiation \[[@B4]\]. Recently, TGFβ1-treated fetal hepatocytes were found to behave as liver progenitors and also gain expression of CK19 \[[@B24]\]. The data from our study suggest that TGFβ1 signaling can lead to transdifferentiation without any changes in the HNF6 expression in the adult liver upon need. It is possible that other transcription factors like OC-2 known to have overlapping target genes of HNF6 \[[@B32]\] may be responsible for the TGFβ1 increase in the periportal hepatocytes.

The periportal hepatocytes expressed CK19 after DAPM challenge with or without BDL pointing to the source of the likely pool of hepatocytes capable of undergoing transdifferentiation. These results are also consistent with our previous findings indicating that subpopulation of periportal hepatocytes represents the progenitor pool from which biliary cells may emerge in situations of compromised biliary proliferation \[[@B1]\].

Taken together the findings from this study indicate that the hepatocytes constitute facultative stem cells for the biliary cells capable of repairing liver histology when the classic biliary regeneration fails. The findings also suggest that subpopulations of hepatocytes in periportal region may have a higher tendency to function as facultative stem cells compared to other cells of their kind, even though they function as hepatocytes under normal circumstances. The exact molecular mechanisms that govern interchange in expression of cell-specific HNFs remain to be elucidated. Our earlier study with hepatocyte organoid cultures point to the role of HGF and EGF in hepatobiliary transdifferentiation \[[@B4]\]. Via AKT independent PI3 kinase pathway, HGF and EGF promote hepatocyte to BEC transdifferentiation \[[@B4]\]. It is also known that Foxo transcription factors are regulated by the PI3 kinase/AKT pathway \[[@B33]\]. It is possible that similar signaling occurs through HGF and/or EGF via PI3 kinase regulating expression of HNF transcription factors that in turn lead to transdifferentiation. Overall, understanding of transdifferentiation of native hepatocytes and BECs may prove to be pivotal in cellular therapy against liver diseases.

Conclusions
===========

Under compromised biliary regeneration, transdifferentiation of hepatocytes into biliary cells provides a rescue mechanism. Periportal hepatocytes undergoing transdifferentiation gradually loose the expression of hepatocyte master regulator HNF4α and acquire HNF1β that shifts cellular profile towards biliary lineage. An increase in TGFβ1 expression in periportal region also appears to be important for the shift from hepatocytic to biliary cellular profile.

Methods
=======

Materials
---------

Collagenase for hepatocyte isolation was obtained from Boehringer Mannheim (Mannheim, Germany). General reagents and 4,4\'-Methylenedianiline (DAPM) were obtained from Sigma Chemical Co. (St. Louis, MO). Primary antibodies used are: CK19 (Dako Corp; 1:100), HNF4α (Santa Cruz; 1:50), HNF6 (Santa Cruz; 1:50), HNF1β (Santa Cruz; 1:100), TGFβ1 (Santa Cruz; 1:200). Biotinylated secondary antibodies were obtained from Jackson Laboratories. Target retrieval solution was obtained from Dako Corp. ABC kit and diaminobenzidine (DAB) kit were from Vector Laboratories.

Animals
-------

DPPIV positive Fisher 344 male rats were obtained from Charles River Laboratories (Frederick, MD). DPPIV negative Fisher 344 male rats were obtained from Harlan (Indianapolis, IN). The animal husbandry and all procedures performed on the rats employed for these studies were approved under the IACUC protocol \#0507596B-2 and conducted according to National Institute of Health guidelines.

Generation of rats with chimeric livers
---------------------------------------

DPPIV chimeric livers were generated as previously described \[[@B3],[@B21]\]. Briefly, male DPPIV negative Fisher rats (200 g) were given two intraperitoneal injections of retrorsine (30 mg/kg), dissolved in water. The injections were given 15 days apart. A month after the last injection, the rats were subjected to PHx. During the PHx operation, the rats were also injected directly into the portal circulation (via a peripheral branch of the superior mesenteric vein) with 3.5 million hepatocytes isolated from DPPIV positive male Fisher rats (200 g). The animals were left to recover and were not subjected to any other experimental procedures for the next 3 months. Assessment of the degree of engraftment was made under direct microscopic observation of sections from the chimeric livers, stained for DPPIV. The percentage of DPPIV positive and negative cells was estimated at 40× magnification in optic fields that included at least one portal triad and one central vein. The percentage of DPPIV-positive cells varied from one lobule to another. The range of engraftment per optic field (as defined above) within each animal varied from 30% to 60%.

Treatment with DAPM
-------------------

Biliary toxicant DAPM (50 mg/kg, dissolved in DMSO at a concentration of 50 mg/ml) was injected intraperitoneally to either DPPIV chimeric or DPPIV positive male Fisher 344 rats every 2 days. In the pilot study, bile duct injury after single injection of DAPM was at its peak at 24 and 48 h after treatment (Figure [1A, B](#F1){ref-type="fig"}) while PCNA analysis indicated that the biliary cells begin cell division at 48 h (Figure [1C](#F1){ref-type="fig"}). Based on these findings, we chose to administer DAPM (50 mg/kg, ip) every 2 days. This treatment was continued for total 3 times and the rats were sacrificed at day 30 after the last DAPM injection (Figure [2A](#F2){ref-type="fig"}). The livers were harvested and utilized for DPPIV histochemistry.

Additional two groups of normal rats ware given either intraperitoneal injection of 50 mg DAPM/kg every two days for 3 times (DAPM × 3) or single DAPM injection (50 mg DAPM/kg) two days before the bile duct ligation (DAPM+BDL). At the end of 30 days after the last treatment, rats were sacrificed Blood was collected for serum analysis. Livers were harvested for further analysis.

Bile duct ligation
------------------

Bile duct ligation was performed as previously described \[[@B3]\]. Briefly, the animals were subjected to a mid-abdominal incision 3 cm long, under general anesthesia. The common bile duct was ligated in two adjacent positions approximately 1 cm from the porta hepatis. The duct was then severed by incision between the two sites of ligation.

Immunohistochemistry
--------------------

Paraffin-embedded liver sections (4 μm thick) were used for immunohistochemical staining. For HNF4α and HNF6 staining, antigen retrieval was achieved by steaming the slides 60 minutes in preheated target retrieval solution (Dako Corporation). For CK19 staining the slides were steamed for 20 minutes in high pH target retrieval solution (Dako Corporation) before blocking.

For TGFβ1 staining no antigen retrieval was necessary. The tissue sections were blocked in blue blocker for 20 minutes followed by incubation with pertinent primary antibody overnight at 4°C. The primary antibody was then linked to biotinylated secondary antibody followed by routine avidin-biotin complex method. Diaminobenzidine was used as the chromogen, which resulted in a brown reaction product.
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###### Additional file 1

**Serum ALT levels in F344 rats**. Serum ALT levels after DAPM (50 mg/kg) administration in F344 rats over a time course, where \* indicates statistical difference from the 0h control (P ≤ 0.05).
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###### Additional file 2

**HNF6 immunohistochemistry on liver sections**. (**A**) normal control rats (NRL, normal rat liver), (**B**) rats that underwent DAPM + BDL treatment, or (**C**) repeated DAPM treatment (DAPM × 3). Brown nuclear staining indicates HNF6 positive staining. No appreciable variation in HNF6 expression was noticed in the treatment versus control groups. Scale bar = 100 μm.
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